(PRESS RELEASE) PARIS and LEXINGTON, MA, U.S.A, 27-Mar-2020 — /EuropaWire/ — Sanofi Pasteur collaborates with Translate Bio (NASDAQ: TBIO) to develop a novel mRNA vaccine for COVID-19. Both companies will jointly investigate multiple candidates with the goal of advancing an … Read the full press release
Posted in France, Healthcare, News, Pharma & Biotech, Science
Tagged BARDA, Biomedical Advanced Research and Development Authority, COVID-19, David Loew, infectious diseases, messenger RNA, mRNA, novel mRNA vaccine, pandemic response, Ronald Renaud, Sanofi, Sanofi Pasteur, SARS-CoV-2 vaccine candidates, therapeutics, Translate Bio, vaccines
PARIS, 05-Dec-2017 — /EuropaWire/ — Following a planned interim analysis, the Independent Data Monitoring Committee (IDMC) for the phase III Cdiffense clinical trial program concluded that the probability that the study will meet its primary objective is low. Based on this, Sanofi has … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged Clostridium difficile vaccine, Sanofi, Sanofi Pasteur
LONDON, 03-Mar-2017 — /EuropaWire/ — MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division of Sanofi, today announced an agreement to develop and commercialise MEDI8897 jointly. MEDI8897 is a monoclonal antibody (mAb) for the … Read the full press release
PARIS, 03-Jan-2017 — /EuropaWire/ — Sanofi and its vaccines global business unit Sanofi Pasteur confirmed today the end of their vaccine joint-venture with MSD (known as Merck & Co. Inc., in the United States and Canada), Sanofi Pasteur MSD (SPMSD). … Read the full press release
Posted in Business, France, Healthcare, Pharma & Biotech
Tagged Merck & Co. Inc., MSD, Sanofi, Sanofi Pasteur, vaccine joint-venture
Global introduction of the first Dengue Vaccine gains further momentum with this third approval in a row in an endemic country – With 1.4 million dengue cases reported this year, Brazil stands to gain tremendous value from this new dengue … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged Dengue, Dengue Vaccine, Dengvaxia®, Sanofi, Sanofi Pasteur
– The highest burden of dengue disease globally in endemic countries is in pre-adolescent to adults age group[1],[2],[3] – In a new pooled analysis, dengue vaccine candidate protected two out of three volunteers aged 9 years and older against all four … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged Dengue Vaccine, Dr. Maria Rosario, New England Journal of Medicine, Sanofi Pasteur
The live, oral, ready-to-use tetravalent rotavirus vaccine candidate is designed to protect young children from severe diarrhea Lyon, France, 15-10-2014 — /EuropaWire/ — Sanofi Pasteur, the vaccines division of Sanofi, announced today the start of a phase III clinical trial in India … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged Olivier Charmeil, Rotavirus vaccine, Sanofi Pasteur, Shantha Biotechnics
Study Demonstrates Fluzone High-Dose Vaccine 24.2 Percent More Effective Than Standard-Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older LYON, France, 19-8-2014 — /EuropaWire/ — Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), … Read the full press release
Shan5™ is the first vaccine jointly developed by the Indian company and its parent company Sanofi Pasteur WHO’s decision allows for the purchase of Shan5™ by United Nations agencies Lyon, France, 7-5-2014 — /EuropaWire/ — Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: … Read the full press release
Cdiffense trial to evaluate vaccine against a leading cause of life-threatening, healthcare-associated infections worldwide Lyon, France, 06-8-2013 — /EuropaWire/ — Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today the initiation of its Phase III clinical program … Read the full press release
Posted in Business, France, Healthcare, Pharma & Biotech, Science
Tagged Alain Bernal, C. diff, Cdiffense, Cdiffense Phase III clinical program, Cdiffense trial, Clostridium difficile infection, intestinal disease, Investigational Clostridium Difficile Vaccine, John Shiver PhD, life-threatening infections, Sanofi, Sanofi Pasteur, Sanofi vaccines division, Susan Watkins, symptomatic Clostridium difficile infection (CDI)
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
